Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise

Kidney International

Volumn 70, Issue 2, 2006, Pages 246-250

  Brines, M ^a   Cerami, A ^a  

^a Kenneth S Warren Institute   (United States)

Author keywords

Apoptosis; Erythropoietin; Ischemia reperfusion; Renal injury; Stem cell

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 5; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TUMOR NECROSIS FACTOR ALPHA;

ANALYTIC METHOD; AUTOCRINE EFFECT; BIOLOGICAL ACTIVITY; CAPILLARY; DOSE RESPONSE; ENDOTHELIUM CELL; HEMATOPOIESIS; HUMAN; ISCHEMIA; KIDNEY INJURY; NONHUMAN; PARACRINE SIGNALING; PHYSICAL STRESS; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; SHORT SURVEY; SIGNAL TRANSDUCTION; STROKE; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HUMANS; KIDNEY; KIDNEY DISEASES; REPERFUSION INJURY;

EID: 33746137372     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001546     Document Type: Short Survey

References (27)

1. Fisher JW. A quest for erythropoietin over nine decades. Annu Rev Pharmacol Toxicol 1998; 38: 1-20.
2. Anagnostou A, Lee ES, Kessimian N et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982.
3. Digicaylioglu M, Bichet S, Marti HH et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995; 92: 3717-3720.
4. Marti HH, Wenger RH, Rivas LA et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666-676.
5. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484-494.
6. Maxwell P. HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol 2003; 14: 2712-2722.
7. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820.
8. Schiffl H, Lang SM. Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium. Eur J Med Res 1997; 2: 97-100.
9. Coleman T, Westenfelder C, Toegel F et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin possess markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 2006; 103: 5965-5970.
10. Beleslin-Cokic BB, Cokic VP, Yu X et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 2073-2080.
11. Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E et al. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003; 18: 2538-2544.
12. Bahlmann FH, De Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926.
13. Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet 2005; 365: 1890-1892.
14. Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
15. Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505.
16. Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100: 6741-6746.
17. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907-14912.
18. Cheetham JC, Smith DM, Aoki KH et al. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Strucf Biol 1998; 5: 861-866.
19. Villa P, Bigini P, Mennini T et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971-975.
20. Cuzzocrea S, Mazzon E, di Paola R et al. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 2005; 52: 940-950.
21. Donnahoo KK, Shames BD, Harken AH et al. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999; 162: 196-203.
22. Gorio A, Madaschi L, Di Stefano B et al. Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci USA 2005; 102: 16379-16384.
23. Viviani B, Bartesaghi S, Corsini E et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. J Neurochem 2005; 93: 412-421.
24. Siren AL, Fratelli M, Brines M et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98: 4044-4049.
25. Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 2005; 42: 233-241.
26. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012.
27. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-10531.